Krystal Biotech delivered a clean commercial beat in the third quarter. It earned $2.05 per share on revenue of $127.34 million, topping the $1.84 consensus by 11.4% and the $124.65 million revenue estimate by 2.2%. Revenue grew 30.2% year over year. Reported earnings fell 22.9% from a year ago, but that decline is an accounting artifact rather than a sign of operating weakness. The central tension is elsewhere. Vyjuvek is executing better than ever and the balance sheet now supports a $400 million buyback, yet nearly every pipeline program that was supposed to produce data around year-end has slipped into 2027.

The earnings decline deserves context. Last year's third quarter included a $31.4 million income tax benefit. This quarter carried $17.1 million of tax expense. Beneath that swing, operating income jumped to $71.1 million from $41.4 million, and pretax income rose to $80.1 million from $48.0 million. Total operating expenses were roughly flat while revenue grew by nearly $30 million, so almost all of the incremental revenue fell to the operating line. Two caveats apply to the quality of the beat. Gross margin eased to 94% from 95% in the first two quarters as ex-U.S. mix rises before process optimizations reach those markets. SG&A of $33.7 million, down from $39.9 million in Q2, was helped by an insurance reimbursement, which flatters the sequential expense trend.

The commercial trajectory is the strongest part of the story. Vyjuvek revenue has climbed steadily from $107.1 million in Q4 2025 to $116.4 million, $119.2 million and now $127.3 million, a roughly 7% sequential gain that reignited growth after a soft Q2. U.S. revenue rose to $95.3 million from $91.6 million. Reimbursement approvals moved past 760, up from about 730 last quarter and 660 at year-end. New U.S. prescribers reached 80-plus, up from 60-plus in Q1, which suggests adoption is still broadening rather than plateauing. International revenue rebounded to about $32 million after a flat second quarter weighed down by the German pricing accrual. With German and Italian pricing now concluded, that overhang is gone. Spain is expected by year-end, France recorded its first home administration, and Japan's first-year prescribing restrictions ease around November-December.

The pipeline is where bears have legitimate ammunition:

• KB803 for ocular DEB was guided to a Q4 2026 readout earlier this year. It now waits on a February 2027 last-patient visit after two patients withdrew.
• KB801 enrollment in neurotrophic keratitis was supposed to finish by year-end. It is now running into 2027, slowed by strict eligibility criteria and competition from an approved therapy.
• KB407 cystic fibrosis interim data moved to the first half of 2027.
• The KB707 lung cancer chemo-combination cohort runs to mid-2027.
• The Italy launch shifted from the second half of 2026 to early 2027.

This context matters for the opex guidance cut to $155–165 million from $175–195 million. Some of that reduction likely reflects slower trial spending rather than pure efficiency. Offsetting the delays, KB113 produced an encouraging early signal in Gorlin syndrome. More than 80% of assessed basal cell carcinoma lesions regressed in the three-patient pilot, regression appeared in non-injected lesions, and histology confirmed clearance of an injected lesion in each patient. KB407 was also selected for the FDA's Complex Innovative Trial Design program, and the company reaffirmed a 2027 registrational start.

The buyback marks a shift in posture. Earlier this year, management tied capital return to better pipeline visibility. It is now authorizing up to $400 million over two years even as visibility has, if anything, deteriorated on timing. With more than $1.2 billion in cash and investments, up from $956 million at year-end, the company can afford it. Still, the move signals that management sees Vyjuvek cash generation as durable enough to fund both the pipeline and shareholder returns.

Investor sentiment entered the report negative but improving, rising to -0.12 from -0.20 at the prior report. That is a modest move that leaves expectations cautious rather than enthusiastic. The stock has drifted only 3.6% higher since the open after the August report, to $332.29. It sits about 7.7% above its 200-day moving average but 11% below its September 3 high of $373.31, so shares gave back much of a mid-quarter run. The internal trend readings are mixed: sequential growth is positive while AVWAP remains negative.

The bottom line is that Krystal's commercial engine is accelerating and increasingly self-funding. Prescriber growth, cleared European pricing hurdles and a large buyback all strengthen the core thesis. The pipeline, however, has become a 2027 story across the board. Investors weighing the quarter must decide whether steady Vyjuvek execution and capital return outweigh a broad reset of clinical catalysts, particularly when part of the lower expense guidance reflects delayed trials rather than discipline.